---
figid: PMC8896653__nihms-1780609-f0001
figtitle: The effects of CDK4/6 inhibitors
organisms:
- Homo sapiens
pmcid: PMC8896653
filename: nihms-1780609-f0001.jpg
figlink: /pmc/articles/PMC8896653/figure/F1/
number: F1
caption: CDK4 and CDK6 in association with D-type cyclins inhibit Rb pathway to initiate
  progression from the G1 to S phases of the cell cycle. CDK4/6 inhibitors interfere
  with the function of these kinases and induce growth arrest.
papertitle: The emerging CDK4/6 inhibitor for breast cancer treatment.
reftext: M. Saeed Sheikh, et al. Mol Cell Pharmacol. ;13(3):9-12.
year: '2021'
doi: ''
journal_title: Molecular and cellular pharmacology
journal_nlm_ta: Mol Cell Pharmacol
publisher_name: ''
keywords: Breast cancer | Palbociclib | Ribociclib | Abemaciclib | Dalpiciclib | Fulvestrant
automl_pathway: 0.9628854
figid_alias: PMC8896653__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC8896653__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8896653__nihms-1780609-f0001.html
  '@type': Dataset
  description: CDK4 and CDK6 in association with D-type cyclins inhibit Rb pathway
    to initiate progression from the G1 to S phases of the cell cycle. CDK4/6 inhibitors
    interfere with the function of these kinases and induce growth arrest.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CCND1
  - CCND2
  - CCND3
  - CDK6
  - CDK4
  - E2F1
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - E2F8
---
